Recent BEAM News
- Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) • GlobeNewswire Inc. • 06/26/2024 10:30:00 AM
- Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease • GlobeNewswire Inc. • 06/14/2024 07:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/10/2024 08:30:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 08:42:12 PM
- Beam Therapeutics to Participate in Jefferies Global Healthcare Conference • GlobeNewswire Inc. • 05/30/2024 10:30:00 AM
- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress • GlobeNewswire Inc. • 05/14/2024 08:00:00 PM
- Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference • GlobeNewswire Inc. • 05/08/2024 10:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 11:19:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 11:09:10 AM
- Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/07/2024 10:30:00 AM
- Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) • GlobeNewswire Inc. • 03/26/2024 10:30:00 AM
- Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences • GlobeNewswire Inc. • 02/28/2024 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2024 12:40:17 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2024 12:22:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 11:43:02 AM
- Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones • GlobeNewswire Inc. • 02/27/2024 11:30:00 AM
- Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference • GlobeNewswire Inc. • 02/05/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:26 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/02/2024 09:05:06 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/31/2024 09:47:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 11:55:18 AM
- Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones • GlobeNewswire Inc. • 01/08/2024 11:30:00 AM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM